Aleta’s pipeline targets diverse antigens and indications. Our ability to broadly target cancers illustrates the simple and modular characteristics of the underlying technology. As each program advances in the clinic the portfolio is extended, building upon the first module or concept. For example, the ALETA-001 biologic program to enhance CD-19 CAR-T therapy led us to create a similar approach to enhance BCMA CAR-T therapy (ALETA-005). Similarly, the development of a Her2-targeting module led to the programs that target both Her2 and B7H3 via biologic delivery (ALETA-003) or via CAR-T cell secretion (ALETA-002). The modular nature of the technology is further illustrated by the triple-antigen targeting biologic for AML (ALETA-004).